|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
SUMATRIPTAN WHEN CONCURRENTLY GIVEN IN A PATIENT HAVE INCREASED CHANCES OF DEVELOPING SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|